Major Cause of Myocardial Injury by COVID-19

The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted quite different in composition vs. thrombi obtained from COVID-19 negative patients and thrombi obtained from infected patients with ACS. 

La mayor causa de injuria miocárdica por COVID-19 al descubierto

Myocardial injury is common in patients hospitalized for COVID-19 and has worse prognosis. Regardless its frequency, the mechanism and the kind of myocardial damage associated to COVID-19 remains uncertain.

This is a systematic pathological analysis of 40 hearts of patients that died when hospitalized for COVID-19. It was carried out to identify the pathological mechanisms behind myocardial injury. 

Hearts were divided according to presence of absence of acute myocyte necrosis and the cause behind it. 

Of the 40 hearts, 14 (35%) had evidence of necrosis, mainly in the left ventricle. Compared against necrosis-free subjects, those with clear heart injury were most frequently women, with chronic kidney failure and shorter symptom onset to hospitalization time. 


Read also: MATRIX: Impact of Crossover from Radial Access to Femoral Access.


The presence of obstructive coronary disease (>75% lesions) resulted similar between patients with and without injury. 

A small percentage of patients presenting myocardial injury (21.4%) reached the definition of microscopic MI (necrosis in area > 1 cm2) while the remaining vast majority showed small necrotic areas spread out. 

Thrombi were found in most patients with necrosis (78.6%), but with a small percentage in the epicardial arteries (14.2%). In the rest, thrombi were found in the capillaries, arterioles, and small muscle arteries.  


Read also: TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.


Microthrombi in patient with COVID-19 presented significantly more fibrine and terminal fragments of the C5b-9 complement compared against intra myocardial thrombi of negative patients or the aspirated material of conventional STEMI patients (irrespective of COVID infection).  

Conclusion

The most frequent physiopathological cause of myocardial necrosis in dead COVID patients is microthrombi. They are different in constitution to that of non-infected patients, and STEMI patients, be them infected or not. 

Antithrombotic measures should be assessed to counteract the effect of COVID 19 to the heart. 

CIRCULATIONAHA-120-051828

Original Title: Microthrombis As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.

Reference: Dario Pellegrini et al. Circulation. 2021 Mar 9;143(10):1031-1042. DOI: 10.1161/CIRCULATIONAHA.120.051828.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...